Bruker (BRKR) Stock Forecast, Price Target & Predictions
BRKR Stock Forecast
Bruker stock forecast is as follows: an average price target of $71.67 (represents a 9.15% upside from BRKR’s last price of $65.66) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
BRKR Price Target
The average price target for Bruker (BRKR) is $71.67 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $78.00 to $60.00. This represents a potential 9.15% upside from BRKR's last price of $65.66.
BRKR Analyst Ratings
According to 6 Wall Street analysts, Bruker's rating consensus is 'Buy'. The analyst rating breakdown for BRKR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bruker Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $78.00 | $63.95 | 21.97% | 18.79% |
| May 20, 2024 | Daniel Arias | Stifel Nicolaus | $77.00 | $76.47 | 0.69% | 17.27% |
| May 05, 2021 | Tycho Peterson | J.P. Morgan | $60.00 | $68.86 | -12.87% | -8.62% |
The latest Bruker stock forecast, released on Aug 27, 2024 by Brandon Couillard from Wells Fargo, set a price target of $78.00, which represents a 21.97% increase from the stock price at the time of the forecast ($63.95), and a 18.79% increase from BRKR last price ($65.66).
Bruker Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $78.00 | $78.00 | $77.50 |
| Last Closing Price | $65.66 | $65.66 | $65.66 |
| Upside/Downside | 18.79% | 18.79% | 18.03% |
In the current month, the average price target of Bruker stock is $78.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 18.79% increase as opposed to Bruker's last price of $65.66. This month's average price target is down 0.00% compared to last quarter, and up 0.65% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Wells Fargo | Overweight | Positive | Initialise |
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 07, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Jul 10, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Citigroup | Buy | Buy | Hold |
| May 20, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Feb 15, 2024 | UBS | Buy | Buy | Hold |
| Feb 14, 2024 | Needham | - | Overweight | Upgrade |
| Aug 22, 2022 | Citigroup | - | Buy | Upgrade |
Bruker's last stock rating was published by Wells Fargo on Aug 28, 2024. The company Initialise its BRKR rating from "Overweight" to "Positive".
Bruker Financial Forecast
Bruker Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $854.50M | $742.80M | $681.90M | $685.30M | $708.40M | $638.90M | $588.40M | $595.00M | $683.50M | $608.90M | $570.80M | $554.70M | $627.50M | $511.40M | $424.60M | $424.00M | $599.90M | $521.10M |
| Avg Forecast | $1.16B | $1.01B | $934.80M | $884.80M | $1.07B | $927.70M | $881.49M | $842.03M | $1.01B | $866.94M | $799.47M | $729.88M | $807.45M | $714.61M | $647.82M | $639.76M | $680.10M | $609.98M | $588.22M | $572.58M | $661.93M | $575.19M | $537.10M | $513.06M | $603.36M | $484.92M | $391.49M | $443.92M | $576.91M | $494.16M |
| High Forecast | $1.17B | $1.03B | $949.82M | $899.02M | $1.09B | $942.61M | $895.66M | $855.57M | $1.03B | $881.63M | $812.32M | $741.61M | $807.66M | $727.78M | $658.23M | $650.04M | $691.04M | $619.78M | $598.16M | $582.25M | $673.12M | $584.90M | $546.18M | $521.73M | $613.55M | $493.12M | $398.10M | $451.42M | $586.65M | $502.51M |
| Low Forecast | $1.14B | $998.86M | $923.58M | $874.18M | $1.06B | $916.56M | $870.91M | $831.92M | $1.00B | $857.28M | $789.87M | $721.11M | $807.22M | $703.69M | $640.04M | $632.08M | $671.94M | $602.66M | $580.90M | $565.45M | $653.69M | $568.02M | $530.42M | $506.67M | $595.85M | $478.89M | $386.61M | $438.39M | $569.72M | $488.01M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.05% | 1.07% | 1.04% | 1.05% | 1.00% | 1.04% | 1.03% | 1.06% | 1.06% | 1.08% | 1.04% | 1.05% | 1.08% | 0.96% | 1.04% | 1.05% |
Bruker's average Quarter revenue forecast for Mar 24 based on 1 analysts is $729.88M, with a low forecast of $721.11M, and a high forecast of $741.61M. BRKR's average Quarter revenue forecast represents a -14.58% decrease compared to the company's last Quarter revenue of $854.50M (Dec 23).
Bruker EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $144.90M | $160.50M | $117.50M | $153.10M | $161.40M | $155.30M | $108.00M | $125.70M | $143.90M | $137.20M | $114.60M | $115.80M | $147.40M | $104.80M | $56.80M | $36.00M | $136.90M | $99.60M |
| Avg Forecast | $230.00M | $201.26M | $186.09M | $176.14M | $213.37M | $184.68M | $175.48M | $167.62M | $201.59M | $172.58M | $159.15M | $130.69M | $160.74M | $142.26M | $128.96M | $118.80M | $135.39M | $85.80M | $117.10M | $93.92M | $131.77M | $114.50M | $106.92M | $66.56M | $120.11M | $96.53M | $77.93M | $47.72M | $114.84M | $98.37M |
| High Forecast | $233.70M | $204.49M | $189.08M | $178.97M | $216.79M | $187.64M | $178.30M | $170.32M | $204.83M | $175.50M | $161.71M | $156.82M | $160.78M | $144.88M | $131.03M | $142.57M | $137.56M | $102.96M | $119.07M | $112.70M | $134.00M | $116.44M | $108.73M | $79.88M | $122.14M | $98.16M | $79.25M | $57.27M | $116.78M | $100.03M |
| Low Forecast | $227.24M | $198.84M | $183.85M | $174.02M | $210.80M | $182.46M | $173.37M | $165.61M | $199.17M | $170.66M | $157.24M | $104.55M | $160.69M | $140.08M | $127.41M | $95.04M | $133.76M | $68.64M | $115.64M | $75.13M | $130.13M | $113.08M | $105.59M | $53.25M | $118.61M | $95.33M | $76.96M | $38.18M | $113.41M | $97.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 1.13% | 0.91% | 1.29% | 1.19% | 1.81% | 0.92% | 1.34% | 1.09% | 1.20% | 1.07% | 1.74% | 1.23% | 1.09% | 0.73% | 0.75% | 1.19% | 1.01% |
1 analysts predict BRKR's average Quarter EBITDA for Mar 24 to be $130.69M, with a high of $156.82M and a low of $104.55M. This is -9.81% lower than Bruker's previous annual EBITDA (Dec 23) of $144.90M.
Bruker Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $205.50M | $88.10M | $57.10M | $76.50M | $97.40M | $88.10M | $49.50M | $61.60M | $76.00M | $87.10M | $57.60M | $56.70M | $68.90M | $54.30M | $24.10M | $10.50M | $68.60M | $61.30M |
| Avg Forecast | $177.60M | $148.00M | $118.40M | $100.64M | $157.88M | $112.22M | $94.78M | $85.16M | $137.35M | $91.15M | $75.97M | $71.43M | $101.12M | $93.69M | $72.05M | $64.94M | $106.92M | $57.49M | $66.84M | $51.33M | $86.59M | $65.49M | $56.29M | $35.44M | $83.14M | $46.54M | $8.50M | $14.61M | $87.28M | $55.96M |
| High Forecast | $181.31M | $151.09M | $120.87M | $102.74M | $161.18M | $114.57M | $96.76M | $86.94M | $140.22M | $99.83M | $77.55M | $85.72M | $105.79M | $96.67M | $73.55M | $77.92M | $109.15M | $68.98M | $68.30M | $61.60M | $88.49M | $66.93M | $57.52M | $42.52M | $84.97M | $47.56M | $8.69M | $17.53M | $89.20M | $57.19M |
| Low Forecast | $174.83M | $145.69M | $116.55M | $99.07M | $155.41M | $110.47M | $93.30M | $83.83M | $135.21M | $85.36M | $74.78M | $57.14M | $96.45M | $92.20M | $70.92M | $51.95M | $105.25M | $45.99M | $65.75M | $41.07M | $85.19M | $64.43M | $55.38M | $28.35M | $81.80M | $45.79M | $8.37M | $11.69M | $85.87M | $55.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.03% | 0.94% | 0.79% | 1.18% | 0.91% | 1.53% | 0.74% | 1.20% | 0.88% | 1.33% | 1.02% | 1.60% | 0.83% | 1.17% | 2.83% | 0.72% | 0.79% | 1.10% |
Bruker's average Quarter net income forecast for Mar 24 is $71.43M, with a range of $57.14M to $85.72M. BRKR's average Quarter net income forecast represents a -65.24% decrease compared to the company's last Quarter net income of $205.50M (Dec 23).
Bruker SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $205.20M | $177.60M | $177.90M | $162.70M | $164.70M | $144.80M | $152.20M | $145.70M | $156.50M | $141.40M | $134.70M | $131.90M | $132.90M | $114.90M | $104.30M | $125.60M | $133.10M | $125.90M |
| Avg Forecast | $276.20M | $241.68M | $223.47M | $211.52M | $256.22M | $221.77M | $210.72M | $201.29M | $242.08M | $207.25M | $191.12M | $169.42M | $193.02M | $170.83M | $154.86M | $154.01M | $162.58M | $93.32M | $140.62M | $121.75M | $158.24M | $137.50M | $128.40M | $82.44M | $144.24M | $115.92M | $93.59M | $176.00M | $137.91M | $118.13M |
| High Forecast | $280.64M | $245.57M | $227.06M | $214.91M | $260.34M | $225.34M | $214.11M | $204.53M | $245.97M | $210.76M | $194.19M | $203.30M | $193.07M | $173.98M | $157.35M | $184.82M | $165.20M | $111.99M | $142.99M | $146.10M | $160.91M | $139.82M | $130.57M | $98.92M | $146.67M | $117.88M | $95.17M | $211.20M | $140.24M | $120.13M |
| Low Forecast | $272.89M | $238.78M | $220.78M | $208.98M | $253.15M | $219.11M | $208.19M | $198.87M | $239.17M | $204.94M | $188.82M | $135.53M | $192.97M | $168.22M | $153.01M | $123.21M | $160.63M | $74.66M | $138.87M | $97.40M | $156.27M | $135.79M | $126.80M | $65.95M | $142.44M | $114.48M | $92.42M | $140.80M | $136.20M | $116.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.15% | 1.06% | 1.01% | 1.55% | 1.08% | 1.20% | 0.99% | 1.03% | 1.05% | 1.60% | 0.92% | 0.99% | 1.11% | 0.71% | 0.97% | 1.07% |
Bruker's average Quarter SG&A projection for Mar 24 is $169.42M, based on 1 Wall Street analysts, with a range of $135.53M to $203.30M. The forecast indicates a -17.44% fall compared to BRKR last annual SG&A of $205.20M (Dec 23).
Bruker EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 2 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.41 | $0.60 | $0.39 | $0.52 | $0.66 | $0.60 | $0.33 | $0.41 | $0.50 | $0.58 | $0.38 | $0.37 | $0.45 | $0.35 | $0.16 | $0.07 | $0.45 | $0.40 |
| Avg Forecast | $1.20 | $1.00 | $0.80 | $0.68 | $1.07 | $0.76 | $0.64 | $0.58 | $0.93 | $0.62 | $0.51 | $0.47 | $0.68 | $0.63 | $0.49 | $0.55 | $0.72 | $0.55 | $0.45 | $0.42 | $0.59 | $0.44 | $0.38 | $0.33 | $0.56 | $0.31 | $0.06 | $0.23 | $0.59 | $0.38 |
| High Forecast | $1.23 | $1.02 | $0.82 | $0.69 | $1.09 | $0.77 | $0.65 | $0.59 | $0.95 | $0.67 | $0.52 | $0.47 | $0.71 | $0.65 | $0.50 | $0.56 | $0.74 | $0.56 | $0.46 | $0.43 | $0.60 | $0.45 | $0.39 | $0.33 | $0.57 | $0.32 | $0.06 | $0.23 | $0.60 | $0.39 |
| Low Forecast | $1.18 | $0.98 | $0.79 | $0.67 | $1.05 | $0.75 | $0.63 | $0.57 | $0.91 | $0.58 | $0.51 | $0.46 | $0.65 | $0.62 | $0.48 | $0.54 | $0.71 | $0.54 | $0.44 | $0.41 | $0.58 | $0.44 | $0.37 | $0.32 | $0.55 | $0.31 | $0.06 | $0.22 | $0.58 | $0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.06% | 0.95% | 0.80% | 0.95% | 0.91% | 1.09% | 0.73% | 0.98% | 0.85% | 1.31% | 1.00% | 1.13% | 0.80% | 1.11% | 2.78% | 0.31% | 0.76% | 1.06% |
According to 1 Wall Street analysts, Bruker's projected average Quarter EPS for Mar 24 is $0.47, with a low estimate of $0.46 and a high estimate of $0.47. This represents a -67.01% decrease compared to BRKR previous annual EPS of $1.41 (Dec 23).
Bruker Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRTC | iRhythm | $76.61 | $144.20 | 88.23% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| BIO | Bio-Rad Laboratories | $326.22 | $565.00 | 73.20% | Hold |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| ZBH | Zimmer Biomet | $106.26 | $137.17 | 29.09% | Hold |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| AORT | Artivion | $25.25 | $30.00 | 18.81% | Buy |
| BRKR | Bruker | $65.66 | $71.67 | 9.15% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
BRKR Forecast FAQ
Is Bruker a good buy?
Yes, according to 6 Wall Street analysts, Bruker (BRKR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of BRKR's total ratings.
What is BRKR's price target?
Bruker (BRKR) average price target is $71.67 with a range of $60 to $78, implying a 9.15% from its last price of $65.66. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bruker stock go up soon?
According to Wall Street analysts' prediction for BRKR stock, the company can go up by 9.15% (from the last price of $65.66 to the average price target of $71.67), up by 18.79% based on the highest stock price target, and down by -8.62% based on the lowest stock price target.
Can Bruker stock reach $100?
BRKR's average twelve months analyst stock price target of $71.67 does not support the claim that Bruker can reach $100 in the near future.
What is Bruker's current price target trend?
1 Wall Street analyst forecast a $78 price target for Bruker (BRKR) this month, up 18.79% from its last price of $65.66. Compared to the last 3 and 12 months, the average price target increased by 18.79% and increased by 18.03%, respectively.
What are Bruker's analysts' financial forecasts?
Bruker's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.72B (high $3.78B, low $3.68B), average EBITDA is $741.14M (high $753.05M, low $732.24M), average net income is $450.04M (high $459.44M, low $443.01M), average SG&A $890.01M (high $904.31M, low $879.32M), and average EPS is $3.04 (high $3.1, low $2.99). BRKR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.99B (high $4.05B, low $3.94B), average EBITDA is $793.49M (high $806.24M, low $783.96M), average net income is $544.64M (high $556.02M, low $536.14M), average SG&A $952.87M (high $968.19M, low $941.43M), and average EPS is $3.68 (high $3.76, low $3.62).
Did the BRKR's actual financial results beat the analysts' financial forecasts?
Based on Bruker's last annual report (Dec 2023), the company's revenue was $2.96B, beating the average analysts forecast of $2.81B by 5.51%. Apple's EBITDA was $557.8M, beating the average prediction of $550.76M by 1.28%. The company's net income was $427.2M, beating the average estimation of $331.8M by 28.75%. Apple's SG&A was $706.9M, beating the average forecast of $672.73M by 5.08%. Lastly, the company's EPS was $2.9, beating the average prediction of $2.35 by 23.29%. In terms of the last quarterly report (Dec 2023), Bruker's revenue was $854.5M, beating the average analysts' forecast of $807.45M by 5.83%. The company's EBITDA was $144.9M, missing the average prediction of $160.74M by -9.85%. Bruker's net income was $205.5M, beating the average estimation of $101.12M by 103.22%. The company's SG&A was $205.2M, beating the average forecast of $193.02M by 6.31%. Lastly, the company's EPS was $1.41, beating the average prediction of $0.683 by 106.37%